Additional Adjuvant Capecitabine in Early Breast Cancer Patients: A Meta-Analysis of Randomized Controlled Trials

References

• Siegel RL , MillerKD, FuchsHEet al. Cancer statistics, 2021. CA Cancer J. Clin.71(1), 7–33 (2021).
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC , LinNU, PolyakK. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov.9(2), 176–198 (2019).
   PubMed Web of Science ®Google Scholar
• Lin NU , VanderplasA, HughesMEet al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer118(22), 5463–5472 (2012).
   PubMed Web of Science ®Google Scholar
• Li X , YangJ, PengLet al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res. Treat.161(2), 279–287 (2017).
   PubMed Web of Science ®Google Scholar
• Peto R , DaviesC, GodwinJet al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet379(9814), 432–444 (2012).
   PubMed Web of Science ®Google Scholar
• Miwa M , UraM, NishidaMet al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer34(8), 1274 (1998).
   PubMed Web of Science ®Google Scholar
• Masuda N , LeeSJ, OhtaniSet al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med.376(22), 2147–2159 (2017).
   PubMed Web of Science ®Google Scholar
• Li J , YuK, PangDet al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial. J. Clin. Oncol.38(16), 1774–1784 (2020).
   PubMed Web of Science ®Google Scholar
• Wang X , WangS-S, HuangHet al. Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001). J. Clin. Oncol.38(Suppl. 15), 507 (2020).
   Web of Science ®Google Scholar
• Lluch A , BarriosCh, TorrecillasLet al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J. Clin. Oncol.38(3), 203–213 (2020).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J , KoeppenH, XiaoYet al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clin. Cancer Res.21(19), 4305 (2015).
   PubMed Web of Science ®Google Scholar
• Steger GG , GreilR, LangAet al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann. Oncol.25(2), 366–371 (2014).
   PubMed Web of Science ®Google Scholar
• Martin M , RuizSimon A, RuizBorrego Met al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. J. Clin. Oncol.33(32), 3788–3795 (2015).
   PubMed Web of Science ®Google Scholar
• Moebus V , Von MinckwitzG, JackischCet al. German Adjuvant Intergroup Node-Positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC vs. ddEC-PwX) in high-risk early breast cancer patients. Ann. Oncol.28(8), 1803–1810 (2017).
   PubMed Web of Science ®Google Scholar
• Li Y , ZhouY, MaoFet al. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Breast Cancer Res. Treat.179(3), 533–542 (2020).
   PubMed Web of Science ®Google Scholar
• Mackelenbergh MV , SeitherF, MöbusVet al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Cancer Res.80(Suppl. 4), GS1–GS07 (2020).
   Web of Science ®Google Scholar
• Knobloch K , YoonU, VogtPM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J. Craniomaxillofac. Surg.39(2), 91–92 (2011).
   PubMed Web of Science ®Google Scholar
• Parmar MK , TorriV, StewartL. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med.17(24), 2815–2834 (1998).
   PubMed Web of Science ®Google Scholar
• Tierney JF , StewartLA, GhersiD, BurdettS, SydesMR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials8(1), 16 (2007).
   PubMed Web of Science ®Google Scholar
• Higgins JPT , GreenS. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0.Wiley-Blackwell, Chichester, England (2008).
   Google Scholar
• Higgins JPT , AltmanDG, GøtzschePCet al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ343, d5928 (2011).
   PubMed Web of Science ®Google Scholar
• Egger M , SmithGD, SchneiderM, MinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ315(7109), 629–634 (1997).
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G , RezaiM, FaschingPet al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40–GeparQuattro). Ann. Oncol.25(1), 81–89 (2014).
   PubMed Web of Science ®Google Scholar
• Muss HB , BerryDA, CirrincioneCTet al. Adjuvant chemotherapy in olderwomen with early-stage breast cancer. N. Engl. J. Med.21(20), 2055–2065 (2009).
   Google Scholar
• Bear HD , TangG, RastogiP,et alNeoadjuvant plus adjuvantbevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondaryoutcomes of a phase 3, randomised controlled trial. Lancet Oncol.16(9), 1037–1048 (2015).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G , KummelS, VogelPetet al. Neoadjuvant vinorelbine–capecitabine versus docetaxel–doxorubicin–cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.. J. Natl Cancer Inst.100(8), 542–551 (2008).
   PubMedGoogle Scholar
• Minckwitz GV , ConradB, ReimerTetet al. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer121120(20), 3639–3648 (2015).
   Google Scholar
• Ohno S , ChowL, SatoNet al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant. Breast Cancer Res. Treat.142(1), 69–80 (2013).
   PubMed Web of Science ®Google Scholar
• Joensuu H , Kellokumpu-LehtinenPL, HuovinenRetet al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncol.3(6), 793–800 (2017).
   PubMed Web of Science ®Google Scholar
• Blum JL , DierasV, LoRusso PMet al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer92(7), 1759–1768 (2001).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J , MilesD, VukeljaSet al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol.20(12), 2812–2823 (2002).
   PubMed Web of Science ®Google Scholar
• Sawada N , IshikawaT, FukaseY, NishidaM, YoshikuboT, IshitsukaH. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin. Cancer Res.4(4), 1013–1019 (1998).
   PubMed Web of Science ®Google Scholar
• Mavroudis D , PapakotoulasP, ArdavanisAet al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann. Oncol.21(1), 48–54 (2010).
   PubMed Web of Science ®Google Scholar